AC Immune (ACIU) Scheduled to Post Quarterly Earnings on Friday

AC Immune (NASDAQ:ACIU) will be issuing its quarterly earnings data on Friday, April 26th.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $16.71 million for the quarter, compared to the consensus estimate of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Price Performance

AC Immune stock opened at $2.37 on Thursday. AC Immune has a 12-month low of $1.78 and a 12-month high of $5.14. The stock has a market capitalization of $234.39 million, a PE ratio of -3.34 and a beta of 1.00. The firm has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $3.34.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of AC Immune in a research report on Friday, March 15th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.